HW
BPMC

Hancock Whitney’s Blueprint Medicines BPMC Stock Holding History

Hancock Whitney’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,777
Closed -$381K – 620
2022
Q3 		$381K Buy
+5,777
New +$371K 0.02% 468
2022
Q2 		– Sell
-4,110
Closed -$263K – 634
2022
Q1 		$263K Sell
4,110
-416
-9% -$29.9K 0.01% 610
2021
Q4 		$485K Sell
4,526
-526
-10% -$55K 0.02% 486
2021
Q3 		$519K Sell
5,052
-26
-0.5% -$2.42K 0.02% 463
2021
Q2 		$447K Buy
5,078
+106
+2% +$9.71K 0.01% 584
2021
Q1 		$483K Sell
4,972
-84
-2% -$8.39K 0.02% 557
2020
Q4 		$567K Buy
+5,056
New +$533K 0.02% 499

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Hancock Whitney's BPMC Position: Q4 2022 in Review

Hancock Whitney sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 5,777 shares — an estimated $381K sold.

Hancock Whitney first reported a position in BPMC in Q4 2020 and held it in 7 quarters. The position peaked at $567K in Q4 2020. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Hancock Whitney reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Hancock Whitney sold 5,777 Blueprint Medicines shares in Q4 2022, an estimated $381K.
  • Hancock Whitney first reported a position in Blueprint Medicines in Q4 2020 and held it in 7 quarters.
  • Hancock Whitney's Blueprint Medicines position peaked at $567K in Q4 2020.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Hancock Whitney's 13F filing for Q4 2022, filed 3 Feb 2023.